Veradermics (MANE) Interest Expenses (2024 - 2026)

Veradermics (MANE) posted Interest Expenses of $66000.0 for Q1 2026, down 99.57% on a QoQ basis from $15.4 million in Q4 2024.

Veradermics (MANE) Interest Expenses (2024 - 2026) Analysis & Trends

Veradermics' Interest Expenses history runs 2 years deep, the most recent figure standing at $66000.0 for Q1 2026.

Quarterly Interest Expenses changed N/A year-over-year to $66000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66000.0 (changed N/A YoY) and the FY2024 annual result came in at $15.4 million, changed N/A from the prior year.
Interest Expenses was $66000.0 for Q1 2026 at Veradermics, down from $15.4 million in the prior quarter.
Across five years, Interest Expenses topped out at $15.4 million in Q4 2024 and bottomed at $66000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-42,141.15
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	32.89 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	16.81 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	420.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	28.30 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	1.17 Bn
10	Veradermics	2.63 Bn	2.63 Bn	-	66,000.00

Download Data